Search results for "Lipide"

showing 10 items of 532 documents

Problématiques de la nutrition en ophtalmologie – application à la dégénérescence maculaire liée à l’âge

2014

Nutrition in ophthalmology – clinical application to age-related macular degeneration «Let food be your medicine.» This contribution from Hippocrates is still timely addressed, especially in the field of ophthalmology. Observational epidemiology reports close associations between food habits and the risk or prevention of several ocular pathologies such as cataract or Age-related Macular Degeneration (AMD). Anti-oxidant vitamins, minerals and lipids are the nutrients that have been the most widely studied. Interventional epidemiology and experimental works partially corroborated these findings. Unexpectedly, the benefit of long chain omega 3 polyunsaturated fatty acids in the prevention of l…

2. Zero hungerretinaGeneral Veterinarygenetic structuresPhilosophyage related macular degenerationfood[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionagingnutrition ; alimentation ; rétine ; lipides ; caroténoïdes ; prévention ; vieillissement ; dégénérescence maculaire liée à l’âge.eye diseasescarotenoid3. Good health[SDV.AEN] Life Sciences [q-bio]/Food and Nutritionprevention ; food ; aging ; age-related macular degeneration. ; diet ; carotenoids ; lipids ; retinaprevention[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organslipid[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory Organssense organs[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansdietHumanities[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies

2021

The metabolic syndrome (MetS) consists of a cluster of metabolic abnormalities including central obesity, insulin resistance, glucose intolerance, hypertension, and atherogenic dyslipidemia [...]

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)QH301-705.5Disease clusterBioinformaticsCatalysisInorganic ChemistryInsulin resistanceDiabetes mellitusmedicineAnimalsHumansObesityPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyMetabolic SyndromeAtherogenic dyslipidemiabusiness.industryOrganic ChemistryAnimals Diabetes Mellitus Type 2 Humans Insulin Resistance Metabolic Syndrome ObesityGeneral Medicinemedicine.diseaseObesityComputer Science ApplicationsChemistryEditorialn/aDiabetes Mellitus Type 2Metabolic syndromeInsulin ResistancebusinessInternational Journal of Molecular Sciences
researchProduct

Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective

2021

Dyslipidemia has been globally recognized, for almost seven decades, as one of the most important risk factors for the development and complications of atherosclerotic cardiovascular disease (ASCVD) [...]

2019-20 coronavirus outbreakFuture perspectiveLipid Metabolism DisorderCoronavirus disease 2019 (COVID-19)Atherosclerotic cardiovascular diseasebusiness.industryEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.diseaseBioinformaticsBiochemistryMicrobiologyQR1-502Editorialn/amedicinebusinessMolecular BiologyDyslipidemialipidi colesterolMetabolites
researchProduct

The effect of bergamot on dyslipidemia

2016

Abstract Background Statins are the most common used lipid lowering drugs but they may cause adverse effects and despite their well-established therapeutic benefits residual cardiovascular (CV) risk remains. The use of other lipid lowering drugs and nutraceuticals alone or as add-on lipid-modifying therapy can be an option in such cases. Several studies have reported health-related properties of the Citrus fruits, among which bergamot (Citrus bergamia Risso) differs from others by particularly high content of certain compounds. Purpose This narrative review summarizes the current evidence on the effects of bergamot on lipid parameters based on studies involving animals and humans. Main evid…

3003CitrusFuture studiesBergamotPharmaceutical Science030204 cardiovascular system & hematologyBioinformatics01 natural sciences03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalDrug DiscoverymedicineAnimalsHumansAdverse effectDyslipidemiasHypolipidemic AgentsFlavonoidsPharmacologyPlant ExtractsChemistryCholesterolMedicine (all)Drug Discovery3003 Pharmaceutical ScienceCardiovascular riskComplementary and Alternative Medicine2708 Dermatologymedicine.disease0104 chemical sciences010404 medicinal & biomolecular chemistryDyslipidemiaComplementary and alternative medicineBiochemistryLDL cholesterolCitrus bergamiaMolecular MedicineNarrative reviewLipid loweringDyslipidemiaPhytomedicine
researchProduct

CLINICAL CHARACTERISTICS AND PLASMA LIPIDS IN SUBJECTS WITH FAMILIAL COMBINED HYPOLIPIDEMIA: A POOLED ANALYSIS

2013

Background. Angiopoietin-like 3 (ANGPTL3) regulates lipoprotein metabolism by modulating extracellular lipases. Loss-of function mutations in ANGPTL3 gene cause familial combined hypolipidemia (FHBL2). The mode of inheritance and hepatic and vascular consequences of FHBL2 have not been fully elucidated. To get further insights on these aspects, we re-evaluated the clinical and the biochemical characteristics of all reported cases of FHBL2. Methods and Results. One hundred fteen FHBL2 individuals carrying 13 different mutations in the ANGPTL3 gene (14 homozygotes, 8 compound heterozygotes and 93 heterozygotes) and 402 controls were considered. Carriers of 2 mutant alleles had undetectable pl…

ANGPTL3 mutations; angiopoietin-like 3; cardiovascular disease; diabetes mellitus; fatty liverSettore MED/09 - Medicina InternaCompound heterozygosityBiochemistryCohort StudiesHypobetalipoproteinemiasEndocrinologyANGPTL3cardiovascular diseaseGenotypeChildLipoproteinclinical characteristicsAged 80 and overbiologydiabetes mellituFatty liverHomozygoteLipoprotein(a)Middle AgedANGPTL3 mutationLipidsCardiovascular Diseasesdiabetes mellitusANGPTL3 Familial combined hypolipidemia LipoproteinAdultmedicine.medical_specialtyHeterozygoteANGPTL3; Familial combined hypolipidemia; clinical characteristicsAdolescentEvinacumabQD415-436Young AdultDiabetes mellitusInternal medicinemedicineHumansANGPTL3 mutationsAlleleFamilial combined hypolipidemiaAgedAngiopoietin-Like Protein 3fatty liverangiopoietin-like 3Cell Biologymedicine.diseaseEndocrinologyAngiopoietin-like ProteinsGene Expression RegulationMutationbiology.proteinPatient-Oriented and Epidemiological ResearchAngiopoietinsLipoproteinLipoprotein(a)
researchProduct

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

2021

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-r…

ATP citrate lyaseEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperlipidemiasPharmacologyLipid-lowering therapyLipid-lowering treatmentMedicineLDL-cholesterolHumansDicarboxylic AcidsHypolipidemic AgentsLdl cholesterolNutrition and DieteticsLipid managementbusiness.industryNovel LDL-C treatment.Fatty AcidsCholesterol LDLBempedoic acidNovel LDL-C treatmentATP citrate lyaseATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatmentLipid loweringCardiology and Cardiovascular MedicinebusinessClinical evaluationBempedoic acidNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

IMPROVE-IT: what have we learned?

2016

Purpose of review: Recent studies and dyslipidemia treatment guidelines indicate that combination lipid-lowering therapy is frequently needed and its use has increased in recent years. Ezetimibe and simvastatin as a fixed dose is an efficacious treatment choice based on positive results of the recent IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). In this review, we discuss recent controversies surrounding ezetimibe and provide clinical perspective on the results of the IMPROVE-IT study. Recent findings: IMPROVE-IT is the first trial that demonstrates a significant clinical benefit of a nonstatin hypolipidemic agent (ezetimibe) used in combination with sta…

Acute coronary syndromeSimvastatinHypercholesterolemia030204 cardiovascular system & hematologyPharmacologyFixed dose03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacotherapyEzetimibeMedicineHumansLow-density lipoprotein cholesterol030212 general & internal medicineAcute Coronary SyndromeIMPROVE-IT trialbusiness.industryCholesterolAnticholesteremic AgentsAnticholesteremic Agentsnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseCardiovascular riskEzetimibeTreatment OutcomechemistrySimvastatinAzetidinesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineDyslipidemiamedicine.drugCurrent opinion in cardiology
researchProduct

Chicken adaptive response to low energy diet: main role of the hypothalamic lipid metabolism revealed by a phenotypic and multi-tissue transcriptomic…

2019

AbstractBackgroundProduction conditions of layer chicken can vary in terms of temperature or diet energy content compared to the controlled environment where pure-bred selection is undertaken. The aim of this study was to better understand the long-term effects of a 15%-energy depleted diet on egg-production, energy homeostasis and metabolism via a multi-tissue transcriptomic analysis. Study was designed to compare effects of the nutritional intervention in two layer chicken lines divergently selected for residual feed intake.ResultsChicken adapted to the diet in terms of production by significantly increasing their feed intake and decreasing their body weight and body fat composition, whil…

Adipose tissueadaptationEnergy homeostasisTranscriptome0302 clinical medicinehypothalamusBeta oxidation2. Zero hunger0303 health sciencesprise alimentaireEndocannabinoid systemAdaptation PhysiologicalCell biologyAlimentation et NutritionBody Composition[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]BiotechnologyResearch Articlelcsh:QH426-470FADS1FADS2lcsh:BiotechnologychickenpouletBiologyModels Biological03 medical and health sciencesQuantitative Trait Heritablelipidlcsh:TP248.13-248.65GeneticsAnimalsFood and Nutritionlipide030304 developmental biologyCaloric RestrictionNeurosciencesLipid metabolismLipid MetabolismDietlcsh:GeneticsGene Expression RegulationNeurons and Cognitionfeed intakeEnergy MetabolismChickenstranscriptome;lipid;feed intake;adaptation;hypothalamus;chickentranscriptome[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgery
researchProduct

Distribution of risk factors, plasma lipids, lipoproteins and dyslipidemias in a small Mediterranean island: The Ustica Project

2003

Background and Aim: The populations of the Mediterranean area have a low incidence of cardiovascular disease (CHD). The aims of this paper are: 1) to present demographic data of the population of Ustica, a small island in the southern part of the Tyrrhenian sea that has reduced communications with the mainland and a diet presumably rich in fish; and 2) to evaluate the distribution of risk fa tors, plasma lipids, lipoproteins and dyslipidemias in this population. Methods and Results: We invited all of the free-living resident population aged more than 14 years (about 800 individuals) to participate in the study; 57 responded, for a participation rate of about 73%. The distribution of cardiov…

AdultAged 80 and overMalerisk factors lipids dyslipidemia Mediterranean populationAdolescentLipoproteinsAge FactorsHyperlipidemiasMiddle AgedDiet MediterraneanLipidsLipoproteins LDLMediterranean IslandsItalyCardiovascular DiseasesRisk FactorsHumansFemaleObesityLipoproteins HDLAged
researchProduct

Increased thioredoxin levels are related to insulin resistance in familial combined hyperlipidaemia

2015

BACKGROUND Thioredoxins (TRX) are major cellular protein disulphide reductases that are critical for redox regulation. Oxidative stress and inflammation play promoting roles in the genesis and progression of atherosclerosis, but until now scarce data are available considering the influence of TRX activity in familial combined hyperlipidaemia (FCH). Since FCH is associated with high risk of cardiovascular disease, the objective of the present study was to assess oxidative stress status in FCH patients, and evaluate the influence of insulin resistance (IR). MATERIALS AND METHODS A cohort of 35 control subjects and 35 non-related FCH patients were included, all of them nondiabetic, normotensiv…

AdultBlood GlucoseMale0301 basic medicinemedicine.medical_specialtyanimal structuresmedicine.medical_treatmentClinical BiochemistryHyperlipidemia Familial Combined030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compoundThioredoxins0302 clinical medicineInsulin resistanceInternal medicinemedicineHumansTriglyceridesGlutathione Disulfidemedicine.diagnostic_testbusiness.industryInsulinCholesterol HDLCase-control studyCholesterol LDLGeneral MedicineGlutathioneMiddle Agedmedicine.diseaseGlutathioneOxidative Stress030104 developmental biologyEndocrinologychemistryCardiovascular DiseasesCase-Control StudiesGlutathione disulfideFemaleInsulin ResistanceThioredoxinLipid profilebusinessOxidative stressEuropean Journal of Clinical Investigation
researchProduct